US 11618784
Anti-CD47 combination therapy
granted A61KA61K2039/505A61K2039/507
Quick answer
US patent 11618784 (Anti-CD47 combination therapy) held by TEVA PHARMACEUTICALS AUSTRALIA PTY LTD expires Mon Mar 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- TEVA PHARMACEUTICALS AUSTRALIA PTY LTD
- Grant date
- Tue Apr 04 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Mar 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 21
- CPC classes
- A61K, A61K2039/505, A61K2039/507, A61K31/663, A61K38/212